The use of combination RT and androgen deprivation therapy in many prostate cancer curative-intent treatment scenarios is supported by level 1 evidence. However, in our current clinical paradigm, we have no ability to determine a priori which patients truly benefit from combination therapy and therefore apply the combination RT and androgen deprivation therapy intensification strategy to all patients, which results in overtreatment or undertreatment of the majority of our patients. Genomics has the ability to more deeply and objectively characterize the disease, in turn refining our prognostication capabilities and enabling the individualization of treatments. We review the commercially available prostate cancer genomic tests, focusing on those able to predict patient outcomes following radiotherapy or guide radiotherapy treatment decisions.

中文翻译：

---

通过放射疗法个性化使用雄激素剥夺疗法的基因组策略。

1级证据支持在许多前列腺癌根治性治疗方案中联合使用RT和雄激素剥夺疗法。但是，在我们目前的临床范例中，我们无法先验确定哪些患者真正受益于联合治疗，因此无法将RT和雄激素剥夺疗法联合治疗策略应用到所有患者，这导致大多数患者过度治疗或治疗不足耐心。基因组学能够更深入，更客观地表征疾病，进而完善我们的预后能力并实现个性化治疗。我们回顾了市售的前列腺癌基因组测试，重点是那些能够预测放疗后患者预后或指导放疗治疗决策的检测。